News - GlaxoSmithKline

Filter

Current filters:

GlaxoSmithKline

Popular Filters

51 to 75 of 446 results

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

04-04-2014

World leading independent biotech firm Amgen revealed in a Securities and Exchange Commission filing…

AmgenAnti-Arthritics/RheumaticsBiotechnologyGlaxoSmithKlineLicensingProliaXgeva

GlaxoSmithKline targets strategic investments in Africa

02-04-2014

Speaking at the 5th EU-Africa Business Forum in Brussels this week, Sir Andrew Witty, chief executive…

FinancialGlaxoSmithKlineHealthcarePharmaceuticalRest of the WorldSouth Africa

GSK drops Phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic in NSCLC

GSK drops Phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic in NSCLC

02-04-2014

UK pharma major GlaxoSmithKline will stop its MAGRIT trial, a Phase III trial of its MAGE-A3 cancer immunotherapeuticin…

GlaxoSmithKlineMAGE-A3OncologyPharmaceuticalResearchUK

GSK withdraws European marketing authorization for ovarian cancer drug Votrient

GSK withdraws European marketing authorization for ovarian cancer drug Votrient

31-03-2014

UK pharma major GlaxoSmithKline has withdrawn its application to the European Medicines Agency for a…

GlaxoSmithKlineOncologyPharmaceuticalRegulationUKVotrientWomen's Health

ACC 2014: GSK’s darapladib disappoints in Ph III trial

ACC 2014: GSK’s darapladib disappoints in Ph III trial

31-03-2014

UK pharma major GlaxoSmithKline (LSE: GSK) presented disappointing data from its pivotal Phase III STABILITY…

Cardio-vasculardarapladibGlaxoSmithKlinePharmaceuticalResearchUKUSA

GSK acquires remaining 30% of its Indonesian Consumer Healthcare business

GSK acquires remaining 30% of its Indonesian Consumer Healthcare business

28-03-2014

US pharma giant GlaxoSmithKline has acquired full ownership of its Indonesian Consumer Healthcare business…

Asia-PacificGlaxoSmithKlineIndonesiaMergers & AcquisitionsPharmaceuticalProduction

Factors driving oncologists’ prescribing decisions for HER2-positive breast cancer patients

Factors driving oncologists’ prescribing decisions for HER2-positive breast cancer patients

28-03-2014

Efficacy, more than any other factors, drives oncologists’ prescribing of targeted therapies for breast…

AfinitorbuparlisibGlaxoSmithKlineHerceptinMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRocheTykerb

Mylan prevails in breach of contract case against GlaxoSmithKline

Mylan prevails in breach of contract case against GlaxoSmithKline

27-03-2014

US generics major Mylan reveals that, after a trial in the US District Court for the District of New…

GenericsGlaxoSmithKlineLegalMylan LaboratoriesNeurologicalparoxetinePaxil-CR

GSK announces delay in Mekinist/Tafinlar MAA; EU approval of Eperzan

GSK announces delay in Mekinist/Tafinlar MAA; EU approval of Eperzan

27-03-2014

UK pharma giant GlaxoSmithKline released a couple of news items yesterday, one slightly negative regarding…

DiabetesEperzanEuropeGlaxoSmithKlineMekinistOncologyPharmaceuticalRegulationTafinlar

Novel collaboration to use genomics and big data to drive drug discovery

27-03-2014

A pioneering public-private research initiative between UK pharma giant GlaxoSmithKline, the European…

BiotechnologyEuropeGlaxoSmithKlineResearch

GlaxoSmithKline’s MAGE-A3 fails in Ph III NSCLC trial

GlaxoSmithKline’s MAGE-A3 fails in Ph III NSCLC trial

20-03-2014

There was another setback for UK pharma giant GlaxoSmithKline with its MAGE-A3 antigen specific cancer…

AgenusGlaxoSmithKlineMAGE-A3OncologyPharmaceuticalResearch

Promising mid-stage results for Prosensa’s drisapersen in DMD boys

19-03-2014

Shares of Dutch biotech firm Prosensa Holding rose 3.85% to $7.02 after the firm reported encouraging…

BiotechnologydrisapersenGlaxoSmithKlineProsensaRare diseasesResearch

Positive results from Anoro Ellipta vs Seretide and Advair Diskus in patients in COPD

Positive results from Anoro Ellipta vs Seretide and Advair Diskus in patients in COPD

14-03-2014

GlaxoSmithKline and Theravance today announced positive results from three Phase III studies with their…

Advair DiskusAnoro ElliptaGlaxoSmithKlinePharmaceuticalResearchRespiratory and PulmonarySeretide

Global epilepsy market to reach $4.5 billion by 2019

Global epilepsy market to reach $4.5 billion by 2019

13-03-2014

The epilepsy therapeutics market value in the eight major countries - the USA, Canada, France, Germany,…

EisaiFycompaGlaxoSmithKlineGlobalMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpat

GSK’s mepolizumab succeeds in Ph III severe eosinophilic asthma trial

GSK’s mepolizumab succeeds in Ph III severe eosinophilic asthma trial

13-03-2014

UK pharma giant GlaxoSmithKline says that a pivotal Phase III study of mepolizumab, an investigational…

GlaxoSmithKlinemepolizumabPharmaceuticalResearchRespiratory and Pulmonary

GSK increases stake in Indian Pharma subsidiary to 75%

GSK increases stake in Indian Pharma subsidiary to 75%

10-03-2014

UK pharma giant GlaxoSmithKline says that, following the voluntary open offer undertaken by its Indian…

Asia-PacificGlaxoSmithKlineIndiaMergers & AcquisitionsPharmaceutical

India/USA trade dispute could impact AIDS treatment programs

10-03-2014

The trade dispute over intellectual property rights between the USA and India is set to derail the distribution…

Anti-viralsCiplaGenericsGilead SciencesGlaxoSmithKlineIndiaPatentsPricingUSA

ISIS Pharma earns $1 million from GSK for advancing ISIS-TTRRx

03-03-2014

USA-based Isis Pharmaceuticals has earned a $1 million milestone payment from UK pharma giant GlaxoSmithKline…

FinancialGlaxoSmithKlineIsis PharmaceuticalsISIS-TTRRxPharmaceuticalRare diseasesResearch

GSK files for US approval for Promacta for severe aplastic anemia

GSK files for US approval for Promacta for severe aplastic anemia

02-03-2014

UK pharma giant GlaxoSmithKline has submitted a supplemental New Drug Application to the US Food and…

GlaxoSmithKlineLigand PharmaceuticalsNorth AmericaOncologyPharmaceuticalPromactaRare diseasesRegulationUSA

Asia-Pacific epilepsy therapeutics market continues to grow as new drugs emerge

28-02-2014

The epilepsy therapeutics market value in the Asia-Pacific region - Australia, China, India and Japan…

Asia-PacificEisaiFycompaGlaxoSmithKlineKeppraMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpatZonegran

Product launches to fuel lupus market growth

28-02-2014

The systemic lupus erythematosus (SLE) treatment market in the seven major countries (7MM) will increase…

Anti-Arthritics/RheumaticsBenlystaBristol-Myers SquibbEli LillyepratuzumabGlaxoSmithKlineGlobalImmuPharmaLupuzorMerck SeronoOrenciaPharmaceuticalRituxanRochetabalumabUCB

Amarin calls on FDA to extend Vascepa exclusivity by five years

28-02-2014

US biotech firm Amarin has filed with a federal court requesting it to order the US Food and Drug Administration…

AmarinBiotechnologyCardio-vascularGlaxoSmithKlineLegalLovazaNorth AmericaUSAVascepa

GSK receives positive CHMP opinion for COPD drug Incruse

GSK receives positive CHMP opinion for COPD drug Incruse

21-02-2014

GlaxoSmithKline has announced that the European Medicines Agency’s Committee for Medicinal Products…

GlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryUKumeclidinium

51 to 75 of 446 results

Back to top